Jump to content

Anastasis

Certifiably Surly
  • Posts

    31444
  • Joined

  • Days Won

    8

Everything posted by Anastasis

  1. Here is a hot take, but fits the data. Biden's prostate cancer was diagnosed a while back. He got on ADT at some point ca. 2022. The ADT was associated with the obvious and manifest cognitive decline. How else do you come out and say that it is hormone sensitive on this timeline? It's really the only way that the pieces fit together.
  2. Any objective reader of the last few pages of this thread can easily identify the clowns.
  3. We had lots of real time conversation here. For example I was a vocal advocate of first dose vax maximization and extended interval second dosing. Just cause you have a short memory does not mean the rest of us do jimmy.
  4. You shouldn't worry about masking. You should worry about wearing a helmet every time you walk out the door.
  5. Agree. The tribal shit still overwhelms any rational discussions. Even at this point and with the benefit of hindsight.
  6. RSV vaccine strategy is an interesting case study in the context of this discussion. Initial recommendations were shared decision making model. That evolved from one year to the next into arguably more restrictive age- and risk-based recommendations. Nobody lost their minds about it. The recommendations just evolved based on experience and context. COVID booster recommendations in the US have been divorced from reality and the rest of the world for some time now. It's long overdue that they are brought in to line.
  7. I got a vacay for telling immamac to fuck off after he told me to fuck off. Leave the kids alone Bojack.
  8. There is nothing wrong with masking in the context of a respiratory infection. But over time masking turned into a matter of social dogma and tribal signaling and not one of epidemiology and risk reduction.
  9. I am not sure that it is my reading comprehension that needs to be questioned in this exchange.
  10. The OSHA rule (which was a epidemiological reasoning hot mess) literally had to get litigated at the Supreme Court. The lack of attention span is amazing. Amazing but not surprising.
  11. What do you think wrt the overall thrust of the regulatory direction? Agree or disagree? Or just pick the nits?
  12. Don’t disagree. Doesn’t mean it is not accurate.
  13. Tell us more about your thoughts on ACIP and vax Adcoms over the last 5 years. Literally every idiot with a log in here thinks that they are tied in cause they have a broke brain twitter feed.
  14. I try to help you clowns, but you try my patience.
  15. You are gonna have to connect those dots for me, I guess. I got a good book of research focussed on vax outcomes, both safety and otherwise. I understand that you dipshits just run out totally unreality based rhetoric and expect it to stick.
  16. Vaccine mandate strategy under Biden resulted in obvious outcomes. This was all litigated here in real time. Attention span is hard.
  17. Oh that was directed squarely at you bitch and you know it. Not sidis.
  18. Maybe. But you know there is a difference twice.
  19. Sounds like bizarro world CR.
  20. Does your quote function not work?
  21. lol. You really this on tilt about the tapper book? Like do you feel really this bad for arguing against obvious reality? Let me ask you a question. How much of your daily media consumption is Twitter and blue sky? Trump dissembling and quoting wholesale gas prices. Are you shocked? I ain’t. Like no self awareness at all.
  22. Agree. The booster recommendations have been outkicking the evidence coverage. This brings us more in line with the recs in the rest of the developed world.
  23. On topic of the thread. More at the link that gets into the study design recommendations and other considerations. https://www.nejm.org/doi/full/10.1056/NEJMsb2506929#f1 An Evidence-Based Approach to Covid-19 Vaccination Authors: Vinay Prasad, M.D., M.P.H., and Martin A. Makary, M.D., M.P.H.Author Info & Affiliations Published May 20, 2025 Over the past 5 years, the United States has moved toward an annual Covid-19 booster program. Each fall, Covid-19 booster shots are developed, alongside seasonal influenza vaccines, and are recommended for every American. As compared with vaccination policies in all European nations, the U.S. policy has been the most aggressive (see Figure 1).1 While all other high-income nations confine vaccine recommendations to older adults (typically those older than 65 years of age), or those at high risk for severe Covid-19, the United States has adopted a one-size-fits-all regulatory framework and has granted broad marketing authorization to all Americans over the age of 6 months.1 The U.S. policy has sometimes been justified by arguing that the American people are not sophisticated enough to understand age- and risk-based recommendations.2 We reject this view. Although the rapid development of multiple Covid-19 vaccines in 2020 represents a major scientific, medical, and regulatory accomplishment,3 the benefit of repeat dosing — particularly among low-risk persons who may have previously received multiple doses of Covid-19 vaccines, had multiple Covid-19 infections, or both — is uncertain. The American people, along with many health care providers, remain unconvinced. Over the past two seasons, uptake of the annual Covid-19 booster has been poor, according to the Centers for Disease Control and Prevention (CDC). Less than 25% of Americans received boosters each year, ranging from less than 10% of children younger than 12 years of age in the 2024–2025 season to 50% of adults over 75 years old.4 Even health care workers remain hesitant, with less than one third participating in the 2023–2024 fall booster program.5 There may even be a ripple effect: public trust in vaccination in general has declined,6 resulting in a reluctance to vaccinate that is affecting even vital immunization programs such as that for measles–mumps–rubella (MMR) vaccination, which has been clearly established as safe and highly effective. In recent years, reduced MMR vaccination rates have been a growing concern and have contributed to serious illness and deaths from measles. Against this context, the Food and Drug Administration (FDA) seeks to provide guidance and foster evidence generation. Moving forward, the FDA will adopt the following Covid-19 vaccination regulatory framework: On the basis of immunogenicity — proof that a vaccine can generate antibody titers in people — the FDA anticipates that it will be able to make favorable benefit–risk findings for adults over the age of 65 years and for all persons above the age of 6 months with one or more risk factors that put them at high risk for severe Covid-19 outcomes, as described by the CDC (Figure 2). For all healthy persons — those with no risk factors for severe Covid-19 — between the ages of 6 months and 64 years, the FDA anticipates the need for randomized, controlled trial data evaluating clinical outcomes before Biologics License Applications can be granted. Insofar as possible, when approving a Covid-19 vaccine for high-risk groups, the FDA will encourage manufacturers to conduct randomized, controlled trials in the population of healthy adults as part of their postmarketing commitment.
×
×
  • Create New...